Core Concept - The term "meme stock" refers to publicly traded companies that experience rapid increases in market value due to trading activity on online platforms, often driven by community interest [1] Company Overview - Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech company focused on drug discovery utilizing artificial intelligence [2] - The company has been suggested to be a meme stock by Jim Cramer, a notable figure in the investment community [5] Stock Performance Analysis - Recursion Pharmaceuticals has been on a downward trend for most of the year, with volatility typical for clinical-stage biotechs [4] - There is limited interest in Recursion on social media, which does not support the classification as a meme stock [4] - Following Cramer's suggestion on October 22, the stock has not consistently increased, underperforming compared to broader equities [6] Investment Viability - A characteristic of meme stocks is that their fundamentals do not correlate with stock performance; however, Recursion's financial performance does not align with the meme stock narrative [7] - Despite being labeled as a meme stock, Recursion Pharmaceuticals may not be a viable investment option [8]